Malignant and trophoblastic cells share the capacity to migrate and invade surrounding tissues; however, trophoblast invasion during implantation is tightly regulated, whereas that associated with tumour progression is not. It is likely that similar mechanisms underlie the dynamic regulation of cell invasion and migration in both cases, and that these are based on epigenetic processes. This hypothesis is supported by recent results demonstrating that expression of the intercellular adhesion molecule E-cadherin, deregulation of which is associated with increased cell motility and invasive potential in cancer, is under epigenetic control in trophoblast cell lines. Further elucidation of the epigenetic pathways shared by trophoblasts and malignant cells is likely to lead to the identification of common diagnostic approaches for the early identification both of cancer and pathological pregnancies involving aberrant trophoblast invasion.
INTRODUCTION
Placentation in human pregnancy involves proliferation, migration and differentiation of the extra-embryonic trophoblast population, and infiltration of the maternal endometrium by invasive EVTs (extravillous cytotrophoblasts). In this ability to proliferate rapidly and invade maternal tissues, invasive EVTs resemble malignant cancer cells [1, 2] , but unlike the latter their invasive potential is precisely regulated and is restricted both temporally and spatially. Deficient trophoblast invasion may result in gestational complications including pre-eclampsia [3, 4] , whereas excessive invasion is characteristic of placenta accreta [5] and of hydatidiform moles that may progress to highly invasive choriocarcinoma [6] .
Trophoblast invasion requires substantial and reversible changes to the cell adhesion phenotype [7, 8] , and in this regard the regulation of functional expression of adheren junction molecules, in particular of E-cadherin, plays a key role in controlling invasive potential. Downregulation of functional E-cadherin expression is also commonly associated with cell invasion and metastasis in a number of human cancers [9] [10] [11] [12] [13] .
Research suggests that identical regulatory mechanisms control invasive potential both in malignant carcinomas and in trophoblasts [1] . Epigenetic control of gene expression through the reversible modification of chromatin has emerged as a fundamental mechanism for the co-ordination of gene expression in a range of systems [14] , most notably in the transcriptional repression of tumour-suppressor genes during tumour progression [15] [16] [17] [18] . We and others have reported that both functional progesterone withdrawal and increased responsiveness to inflammatory stimulus in late pregnancy are sensitive to disruption of epigenetic status [19, 20] , leading to our hypothesis that epigenetic mechanisms play a key co-ordinating role in orchestrating the changes in expression attending major processes and events in normal pregnancy [21] . Thus we speculate that similar molecular mechanisms, involving shared epigenetic processes, also underlie the dynamic regulation of cell migration and invasion in both tumour progression and embryo implantation. In the present article, we highlight recent results in support of this hypothesis, with a focus on our observation of epigenetic regulation of E-cadherin expression in trophoblast cell lines [22] . We anticipate that further research in this area will lead to the development of new diagnostic tools based on epigenetic biomarkers of reduced E-cadherin functionality. These have potential application in the early identification both of pathological pregnancies and cancer, and may lead to new therapeutic strategies targeting aberrant epigenetic states in the respective tissues.
IMPLANTATION AND TROPHOBLAST INVASION
Normal implantation and placentation are critical for a successful pregnancy, and rely on a series of complex interactions between cells of the trophoblast lineage and components of the maternal decidua. Successful implantation results in a well-anchored placenta able to perform efficient gas and nutrient exchange with the maternal circulatory system [23] .
The processes of implantation and placentation are tightly orchestrated. The late blastocyst that enters the uterine cavity 3-4 days after ovulation comprises an inner cell mass, from which the embryo proper arises, and a peripheral trophectodermal layer, which ultimately develops into the placental tissues. Following transmigration across the uterine epithelium, the trophectoderm undergoes a remarkable sequence of differentiation steps resulting in the formation of the maternal-fetal interface [24, 25] . By the tenth day, the trophectoderm has differentiated into a layer of proliferative cytotrophoblasts covered by the multinucleate syncytiotrophoblast layer. Continued cytotrophoblast proliferation and differentiation drives the formation of chorionic villi, which provide a large surface area for fetal-maternal exchange in the mature placenta.
Contact between the tip of a developing villous and permissive decidual extracellular matrix causes activation of the extravillous pathway of trophoblast differentiation, which results in the formation of an anchoring villous and migration of EVTs into the decidualized endometrium. Briefly, non-polarized trophoblast cell columns form at the tips of anchoring chorionic villi, from whence highly mobile spindle-shaped intermediate trophoblasts migrate to infiltrate the endometrium and remodel the maternal spiral arteries within (Figure 1 ). Invasion ceases with terminal differentiation of trophoblasts to non-migratory cell types (large polygonal EVTs and multinucleate giant cells in the endometrium, and endovascular trophoblasts in the walls of utero-placental vessels).
EMT (EPITHELIAL-MESENCHYMAL TRANSITION) AND LOSS OF E-CADHERIN FUNCTION
Trophoblast invasion constitutes a striking example of EMT [26] , in which cell interactions with neighbouring cells and with the ECM (extracellular matrix), which are required for the maintenance of epithelial cell polarity, are disrupted as a critical part of the transition to a mesenchymal phenotype. EMT is a key process in embryogenesis, and reactivation of similar developmental programmes contributes to cancer progression. EMT is associated with acquisition of a migratory and invasive cell phenotype, and is accompanied by concomitant changes in gene expression; disruption of adherens junctions, and especially of E-cadherin function, is a defining feature of EMT events [27] (Figure 2 ).
Figure 2 E-cadherin and the adherens junction
E-cadherin is a 124 kDa transmembrane protein with adhesion and signalling roles that is expressed in epithelial cells. The extracellular domains of E-cadherin homodimers enter homotypic Ca 2+ -dependent-binding interactions with those of dimers on adjacent cells. The intracellular domain of E-cadherin interacts with the actin cytoskeleton via α-catenin and either β-or γ -catenin. Cadherin-catenin complexes constitute the adherens junction.
As a guardian of the epithelial phenotype, E-cadherin has been regarded as a tumour-suppressor gene, and loss of E-cadherin function is an early marker of tumour progression in specific invasive carcinomas [28] . Where this occurs through down-regulation of Ecadherin expression (as opposed to post-translational modification resulting in loss of function, for instance), loss of E-cadherin function not only directly affects cell adhesion, but also leads to accumulation of nuclear β-catenin, thereby triggering a cascade of downstream changes in gene expression through the Wnt signalling pathway [29] . Other adherens complex components are also likely to play dual adhesion/signalling roles as part of the cascade of events leading to EMT. For instance, γ -catenin (plakoglobin) and β-catenin bind to the cytoplasmic domain of E-cadherin in a mutually exclusive manner; thus increased γ -catenin expression in the absence of a corresponding increase in E-cadherin expression leads to displacement of β-catenin from the adherens complex and consequent activation of the Wnt signalling pathway [30] . Thus changes in the expression of adherens complex components may constitute a critical early event in the signalling network orchestrating EMT [31] , in addition to having a direct impact on cell adhesion.
E-cadherin expression is high in the syncytiotrophoblast layer and is down-regulated when cytotrophoblasts leave the villi and invade the interstitial tissue of the decidua [8, [32] [33] [34] . Direct evidence for an inverse correlation between motility and E-cadherin expression among cells of the trophoblast lineage has become available [33, 35] . The observed pattern of expression is absent in placental tissues from spontaneously aborted early pregnancies, reinforcing the hypothesis that Ecadherin down-regulation is a critical requirement for successful implantation [32] .
EPIGENETIC REGULATION OF CANCER-RELATED GENES DURING PLACENTATION
Epigenetic regulation of gene expression is mediated by region-specific reversible modifications of chromatin (principally DNA methylation, post-translational modification of histone proteins and non-coding RNAs), which lead to gene-specific modulation of transcriptional activity [14] . In particular, epigenetic silencing of key tumour-suppressor genes has emerged as an important mechanism in tumour progression, and aberrant DNA methylation in the promoter regions of these genes has been recognized as a useful early marker for cancer states [36] . Thus gene silencing during tumour progression and metastasis through promoter methylation has been observed in various human cancers [37, 38] . In addition, overexpression of DNA methyltransferases DNMT1, DNMT3a and DNMT3b [where DNMT is DNA (cytosine-5-)-methyltransferase], which are the enzymes that catalyse the transfer of methyl groups to CpG residues, has also been reported [39, 40] . A small number of studies have also identified epigenetic regulation of cancer-related genes in trophoblast differentiation and invasion, and these are discussed below.
As described above, loss of E-cadherin function is an early marker of tumour progression. Various mechanisms for this have been described, including genetic mutation, repression by transcription factors and post-translational modification of either the extracellular or cytoplasmic domains [41] [42] [43] [44] . Epigenetic events also play a key role in E-cadherin regulation during neoplastic progression, and promoter hypermethylation, associated with silencing of E-cadherin gene expression, has been reported in various human cancers [41, 43] .
Another epigenetically regulated component of the adherens junctions complex is γ -catenin (plakoglobin) [45] [46] [47] [48] [49] , a multifunctional protein involved in cell-cell adhesion and transcriptional regulation [50] . Loss of γ -catenin expression results in dissolution of adherens junctions and has been associated with neoplastic progression and tumour invasion [51] . DNA methylation of the γ -catenin gene promoter has been identified as a mechanism contributing to loss of γ -catenin expression in prostate cancer [45] , renal cell carcinoma [46] , breast cancer [47] , thyroid cancer [48] and lung cancer [49] .
Few findings are available concerning the regulation of adherens complex component expression in normal trophoblasts. One study has observed strong expression of E-cadherin associated with promoter hypomethylation in cytotrophoblasts from normal firsttrimester placentas [52] . However, the pregnancies investigated ranged from weeks 9 to 11 and would have precluded investigation of trophoblasts in the
Figure 3 Low E-cadherin expression is associated with an invasive cell phenotype
Reduced E-cadherin and γ -catenin expression through promoter hypermethylation is associated with decreased cell adhesion and a transition to an invasive cell phenotype.
early phase of trophoblast invasion. Other studies have observed high E-cadherin expression in villus trophoblast cells derived from normal first-trimester villi with decreased expression in the extravillus trophoblast cells [8] . Our previous studies with trophoblast-derived BeWo cells demonstrate that epigenetic processes are involved in trophoblast invasion [22] . Culture of invasive BeWo cells in the presence of the DNA methylation inhibitor 5-aza-2 -deoxycytidine resulted in a significant up-regulation of E-cadherin and γ -catenin mRNA and protein expression, and promoter activity, with consequent reduction in cell invasion and reversion to an epithelial phenotype. Similarly, we have recently reported that disruption of methylation status in the endometrial epithelial cell line AN3-CA resulted in increased receptivity in an in vitro model of blastocyst attachment, which was correlated with an increase in E-cadherin expression [53] . These findings demonstrate that, in these model systems, key properties relevant to human implantation and placentation are under the control of epigenetic mechanisms that parallel those controlling invasive potential during tumour progression (Figure 3) .
Epigenetic regulation of tumour-suppressor genes in normal placental development and in pathological pregnancies has also been observed in several studies. Maspin [SERPINB5 (serine protease inhibitor B5)], a tumour-suppressor gene involved in the regulation of cell motility, invasion, apoptosis and angiogenesis, is differentially expressed in the cytotrophoblast cells of the placenta during human placental development [54] and is regulated by changes in histone tail modifications [55] . In other studies, aberrant hypermethylation of the tumour-suppressor genes E-cadherin, HIC-1 (hypermethylated in cancer-1) and p16 (a cell-cycle regulator) was frequently observed in hydatidiform mole and choriocarcinoma when compared with normal placenta [52, 56] . Hypermethylation of the tumoursuppressor gene RASSF1A (Ras association domain family 1A) and reduction in gene expression has been observed in human placentas from all three trimesters of pregnancy, whereas expression was absent in other fetal tissues [57] . Hypermethylation of the RASSF1A CpG island was also observed in choriocarcinoma cell lines [57, 58] . The human APC (adenomatous polyposis coli) tumour-suppressor gene is frequently methylated in cancer. Mono-allelic methylation of the APC-1a promoter is also observed in the full-term human placenta with increased methylation of this promoter observed in choriocarcinoma-derived trophoblast cell lines [59] . Another study using genome-wide tissue-specific DNA methylation profiling identified eight genes previously demonstrated to be methylated in cancer which had distinct methylation patterns in human full-term placenta [58] . Within this subset of genes were four negative regulators of the Wnt signalling pathway, which were also found to be methylated in purified first-trimester cytotrophoblasts. Hypermethylation of six of these genes was also observed in choriocarcinoma-derived cell lines [58] . Significantly, two studies from Saffery and coworkers [58, 59] implicate epigenetic regulation of the Wnt signalling pathway in human placentation.
The onset of pre-eclampsia is often associated with shallow or deficient trophoblastic invasion in the first third of the myometrium [3, 4] . In this regard it is interesting to note that increased expression of tumoursuppressor genes has been observed in placenta from pre-eclamptic pregnancies, suggesting that failure to complete the final stages of trophoblast invasion and conversion of maternal blood vessels may underlie pre-eclampsia [60] . Consequently, protection against maternal vessel invasion may be over-reactive in preeclampsia, although the involvement of epigenetic mechanisms was not investigated. However, hypomethylation of the promoters of the tumour suppressors maspin (SERPINB5) and α 1 -antichymotrypsin (SERPINA3) has been observed in maternal serum cell-free DNA, which is thought to originate from the placenta, in pre-eclampsia cases compared with controls, suggesting that epigenetic alterations may be associated with this disease [61, 62] .
SUMMARY AND OUTLOOK
Successful placentation requires well-regulated trophoblast invasion of the endometrium. A better understanding of the molecular mechanisms controlling trophoblast invasion is the key to the identification of new therapeutic strategies for the diagnosis and treatment of diseases arising from aberrant invasion, which is a major cause of spontaneous miscarriage and of complications in pregnancy.
Although placentation is a physiological process, the behaviour of trophoblasts during implantation bears a striking resemblance to the invasive growth that is characteristic of tumour progression, and there is growing awareness that corresponding molecular mechanisms underlie this phenotypic similarity [1] . The comparison does have limits; for example, while trophoblasts are deported from the uterus via the maternal circulation, they do not form secondary colonies at distal sites, and thus there is no trophoblast-based equivalent to metastatic growth in cancer. The broad parallels between tumour progression and trophoblast invasion are likely to conceal significant mechanistic differences; in this regard it is interesting to note that maspin expression appears to be controlled by DNA methylation status in some cancer cell lines, but by histone modification status in the placenta [55] . Nevertheless, the fields of cancer and trophoblast research have much to offer one another.
The down-regulation of E-cadherin function as a prerequisite for conversion into an invasive phenotype represents an example of strong correspondence between trophoblast invasion and tumour progression.
Although not yet proven in normal trophoblasts, we believe that epigenetic mechanisms underlie the molecular control of E-cadherin expression in placentation. Further research with primary trophoblast culture is required to confirm this result; accessing primary tissues remains the principal challenge in trophoblast research.
The emergence of epigenetic silencing as a key mechanism for the regulation of gene expression in general is beginning to focus interest on the search for new therapeutic approaches targeting aberrant epigenetic states. Thus the use of methylation inhibitors to target silencing of tumour-suppressor genes in lung cancer is under investigation [63] , and the use of methyl donors to negate phenotypic changes brought about in Agouti mice through promoter hypomethylation has previously been reported [64] . Novel epigenetic targets for the diagnosis and treatment of pathological pregnancies are very likely to be identified in the next few years; given the recent trend of convergence in cancer and trophoblast research, such therapeutic approaches are likely to be adapted from, and contribute to, corresponding new strategies for the diagnosis and treatment of various cancer diseases.
FUNDING
The studies described from the authors' laboratories were supported in part by the National Research Centre for Growth and Development, the Foundation for Science and Technology, and the Breast Cancer Research Trust (NZ). M.D.M. is a recipient of a James Cook Research Fellowship from the Royal Society of New Zealand.
